المؤلفون: Snyder, Alexandra, Makarov, Vladimir, Merghoub, Taha, Yuan, Jianda, Zaretsky, Jesse M, Desrichard, Alexis, Walsh, Logan A, Postow, Michael A, Wong, Phillip, Ho, Teresa S, Hollmann, Travis J, Bruggeman, Cameron, Kannan, Kasthuri, Li, Yanyun, Elipenahli, Ceyhan, Liu, Cailian, Harbison, Christopher T, Wang, Lisu, Ribas, Antoni, Wolchok, Jedd D, Chan, Timothy A

المصدر: New England Journal of Medicine. 371(23)

مصطلحات موضوعية: Clinical Research, Human Genome, Cancer, Genetics, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, CTLA-4 Antigen, Exome, Female, High-Throughput Nucleotide Sequencing, Histocompatibility Testing, Humans, Ipilimumab, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Medical and Health Sciences, General & Internal Medicine

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/0815417gTest

المؤلفون: Wistuba-Hamprecht, Kilian, Martens, Alexander, Heubach, Florian, Romano, Emanuela, Geukes Foppen, Marnix, Yuan, Jianda, Postow, Michael, Wong, Phillip, Mallardo, Domenico, Schilling, Bastian, Di Giacomo, Anna, Maria, Khammari, Amir, Dreno, Brigitte, Maio, Michele, Schadendorf, Dirk, Ascierto, Paolo, A., Wolchok, Jedd, D., Blank, Christian, U., Garbe, Claus, Pawelec, Graham, Weide, Benjamin

المساهمون: Department of Dermatology Tubingen, Germany, University Medical Center Tubingen, Germany, Department of Internal Medicine II Tübingen, Germany, University Medical Center Tübingen, Germany, Immunité et cancer (U932), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie Paris -Institut National de la Santé et de la Recherche Médicale (INSERM), The Netherlands Cancer Institute Amsterdam, The Netherlands, Memorial Sloane Kettering Cancer Center New York, Weill Medical College of Cornell University New York, Istituto Nazionale Tumori Fondazione Pascale Naples, Italy, Department of Dermatology Essen, Germany, Universität Duisburg-Essen = University of Duisburg-Essen Essen -University Hospital Essen (AöR)-West German Cancer Center Essen, Germany, German Cancer Consortium Heidelberg (DKTK), Division of Medical Oncology and Immunotherapy Siena, Italy, University Hospital of Siena, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), School of Science and Technology Nottingham, U.K., Nottingham Trent University, Division of Cancer Studies London, UK, King‘s College London, Parts of this study were funded by Bristol-Myers Squibb (Munich, Germany) to B Weide. Parts of this study were funded by the EU Seventh Framework Program ‘PRIAT’ (Profiling Responders In Antibody Therapies) grant agreement no 305309 to C Garbe. Parts of this study were funded by Deutsche Forschungsgemeinschaft DFG PA 361-22/1 to G. Pawelec., European Project: 305309,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,PRIAT(2012)

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://inserm.hal.science/inserm-01808248Test ; European Journal of Cancer, 2017, 73, pp.61 - 70. ⟨10.1016/j.ejca.2016.12.011⟩.

مصطلحات موضوعية: Biomarker, Ipilimumab, Effector memory cells, Melanoma, Prognosis, [SDV.CAN]Life Sciences [q-bio]/Cancer

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28167454; info:eu-repo/grantAgreement/EC/FP7/305309/EU/Profiling Responders In Antibody Therapies/PRIAT; inserm-01808248; https://inserm.hal.science/inserm-01808248Test; https://inserm.hal.science/inserm-01808248/documentTest; https://inserm.hal.science/inserm-01808248/file/Wistuba-Hamprecht%20K%20et%20al%20European%20Journal%20of%20Cancer%2073%20%282017%29Eq02.pdfTest; PUBMED: 28167454; PUBMEDCENTRAL: PMC5599126

الإتاحة: https://doi.org/10.1016/j.ejca.2016.12.011Test
https://inserm.hal.science/inserm-01808248Test
https://inserm.hal.science/inserm-01808248/documentTest
https://inserm.hal.science/inserm-01808248/file/Wistuba-Hamprecht%20K%20et%20al%20European%20Journal%20of%20Cancer%2073%20%282017%29Eq02.pdfTest

المؤلفون: Wistuba-Hamprecht, Kilian^1,2 Kilian.Wistuba-Hamprecht@uni-tuebingen.de, Martens, Alexander^1,2, Haehnel, Karin², Geukes Foppen, Marnix³, Yuan, Jianda⁴, Postow, Michael A.^4,5, Wong, Phillip⁴, Romano, Emanuela⁶, Khammari, Amir⁷, Dreno, Brigitte⁷, Capone, Mariaelena⁸, Ascierto, Paolo A.⁸, Demuth, Ilja^9,10, Steinhagen-Thiessen, Elisabeth⁹, Larbi, Anis¹¹, Schilling, Bastian^12,13, Schadendorf, Dirk^12,13, Wolchok, Jedd D.^4,5, Blank, Christian U.³, Pawelec, Graham^2,14,15

المصدر: European Journal of Cancer. Sep2016, Vol. 64, p116-126. 11p.

مصطلحات موضوعية: *MELANOMA prognosis, *BIOMARKERS, *CELL differentiation, *LACTATE dehydrogenase, *MELANOMA, *PROBABILITY theory, *T cells, *PHENOTYPES, *IPILIMUMAB, *DESCRIPTIVE statistics